Half-life
Varies by administration route; IV bolus cleared within hours
Evidence Level
Moderate Evidence
Mechanism of Action
Serves as electron carrier in cellular respiration. Activates sirtuins (SIRT1-7) and PARP enzymes involved in DNA repair, gene expression, and stress responses.
Published Research Ranges & Study Context
Studies have administered: Oral: 250–1000mg/day studied; IV infusions: 250–1500mg per session in clinical studies
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
Multiple studies show NAD+ decline with age correlates with metabolic dysfunction. Human trials show elevation of NAD+ metabolites and improvements in muscle function and fatigue.
Moderate Evidence
Phase 1/2 human trials available
Side Effects Observed in Research
IV infusions: flushing, nausea, fatigue during infusion. Oral forms generally well-tolerated.
Available Configurations (SKU Reference)
NJ100
NJ500
NJ1000
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on NAD+ — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.